Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Capecitabine
Xeloda
Routinely available
SMC (401/07)
29/03/2023
Indication
First line treatment of patients with advanced gastric cancer in combination with a platinum-based chemotherapy regimen
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available
Formulation
150mg, 500mg tablets
Comments
-